【摘要】 目的通过观察轻度持续性哮喘儿童规律雾化吸入推荐剂量吸入型糖皮质激素(ICS)后症状的动态变化,了解哮喘儿童始动雾化吸入ICS后症状得到明显改善并趋于达到最佳疗效的时间。方法 50例既往未使用过ICS规范治疗的轻度持续性哮喘儿童采用喷射式雾化器吸入布地奈德混悬液(BIS)治疗。治疗期间患儿家长使用哮喘日记的形式每日对哮喘症状分别进行日间和夜间评分,每周随访1次,总疗程12w。分别对治疗1～12w哮喘症状评分进行控制评估,并对周-周之间的评分及控制评估行两两比较。结果日间、夜间症状评分和按需吸入速效β2受体激动剂次数第3～12周与第1、2周比较,差异有统计学意义(均p<0.05);第3～12w之间周-周比较差异无统计学意义(日间症状评分t=1.09～0.00,p=0.28～1.00;夜间症状评分t=0.81～0.00,p=0.42～1.00;按需吸入速效β2受体激动剂次数t=1.27～0.00,p=0.21～1.00);连续应用2周以后患儿的完全控制比例呈明显上升达82%,并维持至疗程结束。结论轻度持续性哮喘儿童规律雾化吸入ICS治疗2w其症状即能得到明显改善。由此推测,婴幼儿喘息雾化吸入ICS试验性治疗判断是否有效的观察时间以2w后为宜。更多还原

【Abstract】 ObjectiveTo evaluate the clinical effects of budesonide inhalation suspension (BIS) with nebulizer on children with mild persistent asthma,and to define the time of reaching significant effect after administration of BIS.Methods 50 children with mild persistent asthma were nebulized with BIS for 12 weeks,BIS 1 000 μg/d was administered in the first 6 weeks,then the dose of BIS decrease to 500 μg/d,symptom scores of asthma and the amount of use inhaled β2-agonist were recorded everyday.Results There were significant differences in the asthma symptom scores and the amount of use inhaled β2-agonist between the first two week and 3,4,6,9,12 week after treatment with BIS (p<0.05 for all),but there were no statistical differences between 3,4,6,9,12 week.The clinical effective rates increased significantly after 2 weeks’ treatment (82%),and reached to 84% in week 12.Conclusion The time of reaching significant effect on symptoms control of asthma was about 2 weeks after treatment with BIS.And it is inferred that the period to determine nebulizing BIS treatment is effective or not should be more than 2 weeks.更多还原